TY  - JOUR
AU  - Tix, Tobias
AU  - Alhomoud, Mohammad
AU  - Shouval, Roni
AU  - Iacoboni, Gloria
AU  - Scheffer Cliff, Edward R
AU  - Hansen, Doris K
AU  - Usmani, Saad Z
AU  - Salles, Gilles
AU  - Perales, Miguel-Angel
AU  - Cordas Dos Santos, David M
AU  - Rejeski, Kai
TI  - Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.
JO  - Molecular therapy
VL  - 33
IS  - 7
SN  - 1525-0016
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2025-00681
SP  - 3163-3176
PY  - 2025
N1  - Volume 33, Issue 7, 2 July 2025, Pages 3163-3176
AB  - Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and meta-analysis examined non-relapse mortality (NRM) with BsAb therapy in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). A PubMed and Embase search up to October 2024 identified 29 studies (21 NHL, 8 MM) involving 2,535 patients. The overall NRM point estimate was 4.7
LB  - PUB:(DE-HGF)16
C6  - pmid:40170355
DO  - DOI:10.1016/j.ymthe.2025.03.048
UR  - https://inrepo02.dkfz.de/record/300219
ER  -